A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.

Start Date03 Aug 2026

Sponsor / Collaborator

Hangzhou Sciwind Biosciences Co., Ltd.

NCT07628127

/ RecruitingPhase 1

A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

Start Date06 Jul 2026

Sponsor / Collaborator

Verdiva Bio Dev Ltd.

NCT07553299

/ Active, not recruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities

The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.

Start Date12 Jun 2026

Sponsor / Collaborator

Verdiva Bio Dev Ltd.

100 Clinical Results associated with Ecnoglutide

100 Translational Medicine associated with Ecnoglutide

100 Patents (Medical) associated with Ecnoglutide

Literatures (Medical) associated with Ecnoglutide

01 Sep 2026·DIABETES OBESITY & METABOLISM

Effect of a Novel GLP ‐1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants

Article

Author: Li, Fengshan ; Hu, Feng ; Shi, Shuxia ; Zheng, Qing ; Shi, Wei ; Chen, Zhuo ; Huang, Yalin ; Du, Dan ; Yang, Liu ; Yu, Qin ; Du, Chunfeng ; Li, Yao ; Liu, Xiaohong ; Liu, Rui ; Yang, Ming ; Guo, Weiyi ; Cai, Linrui ; Zou, Qin ; Guan, Lei ; Feng, Shiyin

ABSTRACT:

Aim:

Evaluate ecnoglutide (XW003) effects on rosuvastatin and digoxin pharmacokinetics (PKs) in healthy adults.

Methods:

This was an open‐label, single‐sequence crossover Phase 1 study. Eligible participants received rosuvastatin (10 mg, single dose) and digoxin (0.25 mg, single dose) in two periods: Once before subcutaneous treatment with ecnoglutide and once during steady‐state subcutaneous ecnoglutide (1.2 mg). Coadministration effect was assessed via PK parameters of both drugs.

Results:

A total of 28 volunteers received at least one dose of study drug. Co‐administration of ecnoglutide did not affect rosuvastatin and digoxin to a clinically relevant degree. For the area under the concentration‐time curve from time zero to infinity, the geometric mean (GM) ratio (with ecnoglutide vs. alone) [90% confidence interval (CI)] was 106% (94%, 120%) for rosuvastatin and 84% (76%, 94%) for digoxin. Additionally, the maximum plasma concentration ( Cmax ) of digoxin decreased from 1.39 to 1.31 ng/mL but remained within the therapeutic window. The most common adverse events (AEs) were weight loss and gastrointestinal AEs, which are pharmacologically associated with glucagon‐like peptide‐1 (GLP‐1). No serious AEs were reported. Notably, ecnoglutide treatment led to substantial body weight reduction, with a mean decrease of 11.2% across the 14‐week intervention.

Conclusion:

Based on the PK and safety evaluations, ecnoglutide does not cause clinically significant PK interactions with rosuvastatin or digoxin. Consequently, no dose adjustments for rosuvastatin or digoxin are required when ecnoglutide is co‐administered. However, close clinical and plasma monitoring is advised during the coadministration of digoxin, especially in patients with renal impairment.

01 May 2026·Endocrinology, diabetes & metabolism

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Review

Author: Babar, Rayan ; Kumar, Sumet ; Kumar, Laksh ; Ahmed, Hanzlah ; Ali, Ayesha Sarwar ; Qazi, Hadia ; Ali, Sana Mohammad ; Kumar, Mukesh ; Chaulagain, Aayush ; Raja, Adarsh ; Ali, Sheikh Muhammad Ebtehaj ; Gul, Khizra ; Hanif, Fatima ; Bukhari, Shehzadi Umme Rubab ; Janjua, Arshia Arif ; Sheikh, Rumaisa Imtiaz

ABSTRACT:

Background:

Type 2 diabetes mellitus (T2DM) affects over 500 million people worldwide, with traditional therapies often failing to maintain long‐term glycaemic control. Ecnoglutide, a novel long‐acting GLP‐1 receptor agonist, has emerged as a promising therapeutic option. This systematic review and meta‐analysis evaluated the efficacy and safety of ecnoglutide in adults with T2DM.

Methods:

Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, ClinicalTrials.gov , and Google Scholar through September 2025. Randomized controlled trials comparing ecnoglutide with placebo or active comparators in adults with T2DM were included. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included fasting plasma glucose, insulin resistance markers, lipid profile, liver enzymes, and adverse events. Risk of bias was assessed using the Cochrane RoB‐2 tool. Meta‐analysis was performed using random‐effects models, with mean differences and risk ratios calculated at 95% confidence intervals.

Results:

Four RCTs comprising 1643 participants (1162 receiving ecnoglutide, 444 controls) were included. Ecnoglutide significantly reduced HbA1c (MD = −0.44, 95% CI −0.55 to −0.33, p < 0.00001), body weight (MD = −5.63, 95% CI −7.90 to −3.35, p < 0.01), and fasting plasma glucose (MD = −0.81, 95% CI −1.03 to −0.59, p < 0.00001). Improvements were observed in insulin sensitivity, lipid profile, and liver enzymes. Adverse events occurred more frequently with ecnoglutide (RR = 1.09, p < 0.01), although predominantly gastrointestinal and mild‐to‐moderate, with no significant differences in serious adverse events.

Conclusions:

Ecnoglutide demonstrates robust efficacy in glycaemic control, weight reduction, and cardiometabolic parameters with an acceptable safety profile in adults with T2DM, supporting its therapeutic potential as a next‐generation GLP‐1 receptor agonist.

01 Jan 2026·Frontiers in Pharmacology

No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.

Article

Author: Yu, Qin ; Chen, Zhuo ; Shi, Shuxia ; Cai, Linrui ; Huang, Yalin ; Zheng, Qing ; Shi, Wei ; Du, Dan ; Yang, Liu ; Li, Fengshan ; Du, Chunfeng ; Li, Yao ; Liu, Rui ; Liu, Xiaohong ; Zhang, Lingli ; Yang, Ming ; Zou, Qin ; Guo, Weiyi ; Guan, Lei ; Feng, Shiyin ; Hu, Feng ; Ning, Jing

Objective:

To characterize the drug-drug interaction (DDI) profile of the novel, long-acting GLP-1 receptor agonist ecnoglutide (XW003) with two widely co-prescribed drugs: metformin and narrow therapeutic index agent, warfarin.

Methods:

In this open-label, fixed-sequence, crossover study, 28 healthy participants received a single dose of warfarin and multiple doses of metformin, both with and without steady-state XW003 coadministration. The primary endpoint was the comparison of systemic exposure, assessed by whether the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of key pharmacokinetic (PK) parameters fell within the 80.00%-125.00% no-effect bounds. The pharmacodynamic (PD) impact on warfarin was evaluated via International Normalized Ratio (INR).

Results:

Coadministration of XW003 did not clinically alter the total systemic exposure (AUC) of metformin or of either S- or R-warfarin enantiomer, as all corresponding GMRs and 90% CIs for AUC met the pre-specified no-effect criteria. While modest reductions in C_max and delays in T_max were observed for both object drugs, warfarin's anticoagulant activity remained unaffected, with INR profiles showing no clinically relevant changes. The safety profile of XW003 was consistent with the GLP-1 receptor agonist class.

Conclusion:

The findings demonstrate the absence of a clinically significant interaction between XW003 and either metformin or warfarin. This supports the concomitant use of XW003 with these medications without dose adjustment, providing crucial evidence for its safe application in real-world clinical practice where polypharmacy is common.

News (Medical) associated with Ecnoglutide

30 Jul 2026

·www.biospace.com

Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

VRB-103, a potential once-weekly, selective oral amylin analog, is being evaluated in a Phase 1 study as both a monotherapy and in combination with VRB-101 (oral ecnoglutide), a once-weekly oral GLP-1 analog Once-weekly oral dosing of both VRB-103 and VRB-101 enabled by clinically validated, potential best-in-class peptide delivery platform VRB-103 is the first known, once-weekly oral amylin analog currently in clinical development Initial data currently anticipated by the end of 2026 LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral candidates for obesity and obesity-related disorders, today announces that the first patient has been dosed in a Phase 1 SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity. The Phase 1 randomized, double-blind, placebo-controlled study will assess the safety and tolerability of VRB-103, in healthy patients with an elevated BMI. The study will evaluate VRB-103 alone and in combination with VRB-101, including assessment of multiple combination dose ratios. Verdiva currently anticipates initial Phase 1 data at the end of 2026 (Study ID: NCT07628127). VRB-103 is the first known once-weekly, amylin receptor-selective, oral amylin peptide analog currently in clinical development. Preclinical data demonstrated VRB-103 to have a differentiated pro strong potency and high amylin receptor selectivity, with a comparable pharmacokinetic pro VRB-101. VRB-103 also leverages Verdiva's investigational proprietary oral peptide delivery platform. “The initiation of the VRB-103 Phase 1 study marks an important milestone for Verdiva and highlights our growing momentum as we move our second oral peptide into the clinic,” said Steve Marso, Chief Medical Officer at Verdiva Bio. “Obesity is a complex, chronic disease, and we’re committed to developing differentiated next-generation obesity candidates. VRB-103 has the potential to deliver a convenient, once-weekly oral treatment, with a clinically meaningful efficacy and tolerability pro patients looking for alternatives to GLP-1 therapies.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); About VRB-103 VRB-103, a once-weekly investigational amylin receptor-selective, oral amylin analog, is being developed to address both the induction and maintenance phases of weight loss in patients living with overweight or obesity. Amylin agonism represents a non-incretin mechanism of action, offering an alternative therapeutic approach for patients with obesity/overweight, potentially including those who do not respond to or cannot tolerate GLP-1 therapies. VRB-103 is designed to be amylin receptor-selective at human amylin receptor-1 and -3 relative to the human calcitonin receptor. VRB-103 is currently being evaluated in a Phase 1 study and is in development as a monotherapy and in combination with VRB-101, a once-weekly oral GLP-1 analog. About Verdiva Bio Verdiva Bio is a next-generation obesity biotech company developing a differentiated portfolio of once-weekly oral drug candidates to help people living with obesity and obesity-related disorders. Using validated science and the Company’s proprietary oral absorption enhancer, Verdiva’s portfolio of once-weekly oral peptide medicines are designed to address the needs of patients across the emerging and diverse obesity market with improved convenience, tolerability, and patient choice. Verdiva Bio’s most advanced investigational candidate, VRB-101, has demonstrated clinical proof-of-concept in Phase 1, including evidence of once-weekly oral dosing feasibility and improved oral bioavailability versus existing daily oral GLP-1 peptides. VRB-101 is currently in Phase 2 development in the United States. The Company is also developing a once-weekly selective oral amylin analog, VRB-103, for use as a monotherapy and in combination with VRB-101, in addition to other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. For more information, please visit . Contacts Verdiva Bio Charlotte Davison, Chief of Staff info@verdivabio.com FTI Consulting (Media) Ben Atwell, Michael Trace ftiverdivacomms@fticonsulting.com

23 Jul 2026

·www.fiercebiotech.com

Chutes & Ladders—Biogen R&D vet gets in Formation

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia, Zoey Becker, or Will Maddox and it will be featured here at the end of each week. Biogen R&D vet gets in Formation AI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers , M.D., Ph.D., is joining the 2025 Fierce 15 honoree as chief scientific officer and head of R&D. Ehlers was a professor of neurobiology at Duke University for more than a decade before pivoting to industry, serving in leadership at Pfizer before moving to Biogen to lead global R&D. He then joined Apple Tree Partners, where he helped found four companies, one of which–Ascidian Therapeutics–he led as CEO for six years until departing this month for Formation. Ehlers was also recently an entrepreneur-partner at MPM BioImpact. "We built Formation Bio around the idea that the best scientists and the best technology should work together," Formation co-founder and CEO Benjamine Liu, Ph.D., said in a release. "Mike has operated at this intersection his entire career, and he's going to be central to how we pick, design, and progress programs that we believe can have an enormous impact on patients worldwide." Release Verdiva adds experienced obesity leader as CMO Steve Marso , M.D., is making the move from chief medical officer at Metsera to obesity-focused Verdiva Bio, where he will serve in the same role. Marso spent two years at Metsera before the company's $10 billion acquisition by Eli Lilly in November. Also making the jump from Metsera to Verdiva is Jason Mallory , who takes on the title of senior vice president of clinical development. Marso will lead Fierce 15 honoree Verdiva's clinical strategy in support of its lead oral obesity-focused programs. These assets include VRB-103, a once-weekly oral amylin analog, and VRB-101, a once-weekly oral GLP-1 peptide analog. The drugs are enabled by Verdiva's proprietary oral absorption enhancer and are designed to improve convenience, tolerability and patient choice in the obesity drug market. Marso, an interventional cardiologist by training, co-authored two New England Journal of Medicine articles that helped raise the profile of Novo Nordisk’s semaglutide. He joins Verdiva as VRB-103 advances through a phase 2 trial in the U.S. Release Sanofi refreshes executive committee Sanofi unveiled a slate of changes to its executive committee that will become effective Sept. 1 as the French drugmaker prepares to unlock its “next strategic chapter.” The executive team is to be made up of leaders across several areas and functions, including R&D, manufacturing, vaccines and specialty care divisions, to name a few. The new names on the executive committee include Jamie Haney , who takes over as general counsel as Roy Papatheodorou hits the exit in favor of “external opportunities” after spending four years with the company. EVP of general medicines Oliver Charmeil , who has been on the executive committee since 2011 and recently came off a stint as interim CEO earlier this year, is pivoting to a new role as strategic projects advisor to CEO Belén Garijo. His previous position will be taken up by Thomas Grenier , who currently heads up vaccines, North America. Meanwhile, as the company reshapes its organizational approach, current head of business operations Madeline Roach will instead become president and country lead of Sanofi Germany, Switzerland and Austria. Her current responsibilities, which include “optimizing enterprise business services,” will be integrated into the finance function under finance EVP François Roger , which will also take on some other new business areas including global partnering. Story > Migraine-focused Mentari Therapeutics appointed Alkermes-acquired Avadel Pharmaceuticals CEO Greg Divis as its new head honcho. Release . > Germany’s Allogenetics is bringing Jeroen Rovers , M.D., Ph.D., onboard to replace founder Rainer Blasczyk as CMO to advance an ex vivo treatment for lung transplantation graft rejection. Release . > Altesa BioSciences aims to continue the momentum of a recent $75 million series B round and launch of a phase 2b clinical trial by appointing Brett Haumann as CEO. Release . > San Francisco-based Revagenix has promoted scientist Peter Smit h, Ph.D., to the CSO spot as its potentially first-in-class inhalable therapy, Rev-56, enters the clinic. Release . > After 13 years with Eli Lilly, head of commercial strategy for blockbuster GLP-1 drug Zepbound, Silvia Luque is switching over to obesity biotech Zealand Pharma, where she’ll serve as head of U.S. marketing. LinkedIn > Neurocrine Biosciences’ Samir Siddhanti , who has been with the company since 2017, snagged a seat on the executive management committee with a promotion to chief business officer. Release > With Michael Ehlers , M.D., Ph.D., stepping down as president and CEO of Ascidian Therapeutics to join Formation Bio, Ascidian’s Chief Financial Officer and Chief Business Officer Daniel Rosan will assume the role of president as the board conducts its CEO succession process. Release > After just 10 months in the role, Lisa Bollinger , M.D., resigned as chief medical officer of lysosomal storage disorder biotech Polaryx Therapeutics. The company said her departure will not impact clinical timelines and that it has begun the search for her replacement. Filing > As Flagship’s Tessera Therapeutics moves its first in vivo gene editor into the clinic, the biotech is saying goodbye to CEO Michael Severino , who is replaced by Joseph Romanelli . Release > Prominent ophthalmologist Mandeep Sagoo , Ph.D., is reinvigorating development of ReBio Pharma’s uveal melanoma candidate as chief medical officer. Release > Teresa Nunes , M.D., is looking to advance gene therapies for epilepsy as the new chief medical officer at the aptly named EpilepsyGTx. Release > Swiss oncology outfit Veraxa Biotech has named Christoph Erkel , Ph.D., as chief scientific officer to take over for the departing Rick Austin , Ph.D.. Release

Executive ChangeAcquisition

23 Jul 2026

·www.biospace.com

Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

Steve Marso, M.D., joins Verdiva as CMO from Metsera, where he held the equivalent position, bringing valuable clinical and regulatory expertise as Verdiva continues development of a unique portfolio of once-weekly oral treatments for obesity Also from Metsera, Jason Mallory joins Verdiva as SVP, Clinical Development to lead Verdiva’s clinical trial design and execution LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral therapies for obesity and obesity-related disorders, today announced that it has strengthened its leadership team with the appointment of Steve Marso, M.D. as Chief Medical Officer (CMO). Steve brings valuable clinical and regulatory experience to Verdiva following his previous roles, including as CMO at Metsera from May 2023 through to its acquisition by Pfizer in November 2025. He will lead Verdiva's clinical strategy and execution, driving forward lead programs, VRB-103, a once-weekly oral amylin analog, and VRB-101, a once-weekly oral GLP-1 peptide analog. “We’re delighted to welcome Steve to Verdiva at a pivotal moment for the Company,” said Khurem Farooq, CEO at Verdiva Bio. “Steve brings with him a wealth of experience and expertise from his time at Metsera where he played a critical role in developing a strong and differentiated portfolio of obesity and metabolic assets. I look forward to working alongside Steve as we deliver on our goal to develop treatments that address patient needs across diverse and emerging obesity market segments.” Steve is a clinical researcher, clinician, author, and executive leader. He has authored a substantial body of peer-reviewed research and is widely regarded for his expertise in analysing clinical trials and health data related to GLP-1 therapies for cardiometabolic disease, including leading the first generation of GLP-1 peptide medications with Novo Nordisk. “I’m thrilled to join Khurem and the wider Verdiva team in their pioneering work to develop a differentiated portfolio of once-weekly oral treatments for obesity,” said Steve Marso, M.D., Chief Medical Officer at Verdiva Bio. “The development of innovative treatments is something I’ve focused much of my career on, and I believe Verdiva’s strong clinical and pre-clinical pipeline is well positioned to deliver much needed solutions for patients across this space.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); In addition to Steve’s appointment as CMO, Jason Mallory has also joined Verdiva as Senior Vice President Clinical Development to lead the design, strategy and execution of Verdiva’s clinical programs. Jason also joins from Metsera where he was SVP, Clinical Development and MET097 (berobenatide) Program Leader. Jason brings deep clinical expertise spanning GLP-1/NuSH therapeutics and cell and gene therapies, built across senior roles at Kriya, Spark Therapeutics and GSK. About Verdiva Bio Verdiva Bio is a next-generation obesity biotech company developing a differentiated portfolio of once-weekly oral drug candidates to help people living with obesity and obesity-related disorders. Using validated science and the Company’s proprietary oral absorption enhancer, Verdiva’s portfolio of once-weekly oral peptide medicines are designed to address the needs of patients across the emerging and diverse obesity market with improved convenience, tolerability, and patient choice. Verdiva Bio’s most advanced investigational candidate, VRB-101, has demonstrated clinical proof-of-concept in Phase 1, including evidence of once-weekly oral dosing feasibility and improved oral bioavailability versus existing daily oral GLP-1 peptides. VRB-101 is currently in Phase 2 development in the United States. The Company is also developing a once-weekly oral (selective) amylin analog, VRB-103, for use as a monotherapy and in combination with VRB-101, in addition to other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. For more information, please visit . Contacts Verdiva Bio Charlotte Davison, Chief of Staff info@verdivabio.com FTI Consulting (Media) Ben Atwell, Mike Trace ftiverdivacomms@fticonsulting.com

Phase 2Executive ChangePhase 1

100 Deals associated with Ecnoglutide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	China	Hangzhou Sciwind Biosciences Co., Ltd.	03 Mar 2026
Overweight	China	Hangzhou Sciwind Biosciences Co., Ltd.	03 Mar 2026
Diabetes Mellitus, Type 2	China	Hangzhou Sciwind Biosciences Co., Ltd.	27 Jan 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	China	Hangzhou Sciwind Biosciences Co., Ltd.	01 Aug 2026
Sleep Apnea, Obstructive	Phase 3	China	Hangzhou Sciwind Biosciences Co., Ltd.	03 Feb 2026
Metabolic Dysfunction Associated Steatohepatitis	Phase 1	China	Hangzhou Sciwind Biosciences Co., Ltd.	16 Jun 2021
Arthritis Pain	IND Approval	China	Hangzhou Sciwind Biosciences Co., Ltd.	27 Apr 2026
Alzheimer Disease	Preclinical	China	Hangzhou Sciwind Biosciences Co., Ltd.	19 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07073417 (ADA2026)	Phase 2	Obesity	163	Ecnoglutide	vmnjseooem(vkhumzutpf) = The most common adverse events were gastrointestinal disorders of mild to moderate severity: diarrhea (30.5% vs 30.9%), nausea (13.4% vs 21.0%), constipation (17.1% vs 11.1%), and vomiting (11.0% vs 12.3%) for ecnoglutide and semaglutide, respectively. odsybdwyxc (lvyqzwsdzt )	Positive	20 Jun 2026
				Semaglutide
NCT05680155 (EECOH-1, Pubmed \| Nat Commun) Manual	Phase 3	Diabetes Mellitus, Type 2	211	Ecnoglutide 0.6 mg	gceyfhttey(csnqhalpqg) = jvqdevqmum temimsmypm (hbscdgexnl, -2.18 to -1.73) Met View more	Positive	07 Jan 2026
				Ecnoglutide 1.2 mg	gceyfhttey(csnqhalpqg) = zsvwsvngpk temimsmypm (hbscdgexnl, -2.65 to -2.20) Met View more
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	iqfmxkhpex(wbgnjeksdg) = bghzsxmuhg sxabxalavd (tivxularnh ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	iqfmxkhpex(wbgnjeksdg) = ewpvcveyjz sxabxalavd (tivxularnh ) View more
NEWS Manual	Phase 3	Obesity	-	ecnoglutide	jwwhaoswec(infwmujxdz) = gnutrymngu ypcdelclxa (heugyvvxht )	Positive	27 Jun 2025
NCT05813795 (SLIMMER, Lancet \| NEWS 1 \| NEWS 2 \| NEWS 3) Manual	Phase 3	Overweight \| Obesity	664	ecnoglutide 1.2 mg	pyivpcotbd(pjjqferjjy) = xohcimacqd xxjcnufriw (xxplbodexm, 0.8) View more	Positive	21 Jun 2025
				ecnoglutide 1.8 mg	pyivpcotbd(pjjqferjjy) = ntjmtbltgf xxjcnufriw (xxplbodexm, 0.9) View more
CTR20211014 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	145	Ecnoglutide 0.4 mg	xxtrfnycsb(bcdqekveiy) = fvpuponetu kinmwaqdis (tipjjqbgif ) View more	Positive	27 Sep 2024
				Ecnoglutide 0.8 mg	xxtrfnycsb(bcdqekveiy) = upmjgvbnen kinmwaqdis (tipjjqbgif )
EASD2024 \| ADA2024	Phase 1	-	56	Oral ecnoglutide 7 mg QD	myetbxdcez(vtqbmpifmr) = The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. There were no serious AEs. One participant experienced a Grade 3 AE of diarrhea that led to study drug discontinuation einzvqrvum (pjazmqyton )	Positive	09 Sep 2024
				Oral ecnoglutide 15 mg QD
NCT05680155 (ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 2	211	Ecnoglutide 0.6 mg	hvhizlesep(ijegpektww) = rotczafejg xtchvlqapk (mxfehcxpwg ) View more	Positive	21 Jun 2024
				Ecnoglutide 1.2 mg	hvhizlesep(ijegpektww) = uunrhopcfu xtchvlqapk (mxfehcxpwg ) View more
NCT05184322 (ADA2024) Manual	Phase 1	Obesity	56	Oral Ecnoglutide 7mg (healthy)	zgkkiekpqd(rphesvhigm) = The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. cmuozaqmrh (vdqqenqhwu ) View more	Positive	21 Jun 2024
				Oral Ecnoglutide 15mg (healthy)
NEWS Manual	Phase 1	Obesity	56	ecnoglutide	kukgxomonu(inypindhww) = 最常见的不良事件包括恶心、头痛、腹泻、呕吐和食欲减退，大多数不良事件的严重程度为轻中度，主要发生在剂量递增期 vrnzzpsudb (zxdywujfzt )	Positive	24 Jan 2024
				placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis